| 中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
|---|---|---|---|---|
| —— | 3-hydrazinoacenaphtho<1,2-e><1,2,4>triazine | 70154-36-8 | C13H9N5 | 235.248 |
| —— | 9-methylsulfanyl-acenaphtho[1,2-e][1,2,4]triazine | 70154-30-2 | C14H9N3S | 251.312 |
| —— | 2-acenaphtho[1,2-e][1,2,4]triazin-9-ylsulfanyl-acetamide | 70154-34-6 | C15H10N4OS | 294.337 |
| —— | 9-(benzylthio)-acenaphtho[1,2-e]-1,2,4-triazine | 70154-32-4 | C20H13N3S | 327.409 |
Cancer is one of the most devastating diseases, affecting the lives of millions of people around the world.
A series of acenaphtho[1,2-e][1,2,4]triazine containing different thiomethyl-1,2,3-triazole derivatives were designed based on a fragment-based and molecular hybridization approach as anti-cancer agents.
Designed compounds were synthesized using cycloaddition condensation followed by click reaction. Cytotoxicity of prepared compounds was evaluated by MTT reduction assay against four different cancer cell lines.
The biological evaluation indicated that derivative 6d with para-fluorobenzyl moiety was the most active cytotoxic agent with IC50 values of 70.1, 12.8, 41.5, and 16.0 μM against K562, MOLT-4, HT-29, and MCF-7 cells, respectively. Cell cycle analysis showed that acenaphtho triazine derivatives could induce G0/G1 phase arrest in MCF-7 breast cancer cells.
Synthesized derivatives can be ideal candidates for further exploration as anti-cancer agents.